Cargando…
A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity
Mammalian INDY (mINDY, NaCT, gene symbol SLC13A5) is a potential target for the treatment of metabolically associated fatty liver disease (MAFLD). This study evaluated the effects of a selective, cross-species active, non-competitive, non-substrate-like inhibitor of NaCT. First, the small molecule i...
Autores principales: | Zahn, Grit, Willmes, Diana M., El-Agroudy, Nermeen N., Yarnold, Christopher, Jarjes-Pike, Richard, Schaertl, Sabine, Schreiter, Kay, Gehrmann, Wiebke, Wong, Andrea Kuan Cie, Zordan, Tommaso, König, Jörg, Jordan, Jens, Birkenfeld, Andreas L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413491/ https://www.ncbi.nlm.nih.gov/pubmed/36005604 http://dx.doi.org/10.3390/metabo12080732 |
Ejemplares similares
-
The Role of INDY in Metabolic Regulation
por: Willmes, Diana M, et al.
Publicado: (2013) -
The longevity transporter mIndy (Slc13a5) as a target for treating hepatic steatosis and insulin resistance
por: Willmes, Diana M., et al.
Publicado: (2016) -
L-Arginine and Cardioactive Arginine Derivatives as Substrates and Inhibitors of Human and Mouse NaCT/Nact
por: Surrer, Daniela B., et al.
Publicado: (2022) -
The NACT Training Package
por: Scarpello, John H. B.
Publicado: (1991) -
Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism
por: Selch, Stefan, et al.
Publicado: (2018)